Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK & DCRI announced publication of positive results from the Harmony Outcomes study which assessed CV safety and efficacy of albiglutide.
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion supporting use of Trelegy Ellipta
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV announced submission of MAA to EMA for a single-tablet, two-drug regimen of DTG and 3TC for the treatment of HIV-1 infection.
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GSK will profile the growing evidence base that supports its broad respiratory medicines portfolio at ERS congress in Paris, France, 09/18.
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc(LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.
GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
Advisory Committee provide non-binding recommendation for consideration by the FDA
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes
GSK delivers improvements in sales, margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.